• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LiverSCA 2.0:用于人类肝细胞癌和肝内胆管癌的增强型综合细胞图谱。

LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

作者信息

Suoangbaji Tina, Long Renwen, Ng Irene Oi-Lin, Mak Loey Lung-Yi, Ho Daniel Wai-Hung

机构信息

State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.

Department of Pathology, School of Clinical Medicine, The University of Hong Kong, Hong Kong.

出版信息

Cancers (Basel). 2025 Mar 5;17(5):890. doi: 10.3390/cancers17050890.

DOI:10.3390/cancers17050890
PMID:40075736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11898674/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by considerable extents of cellular and molecular heterogeneities. We recently developed a web-based cell atlas called LiverSCA that possesses a user-friendly interface and comprehensive functionalities. It facilitates the exploration of gene expression patterns, cellular compositions, and intercellular communication within the microenvironments of liver and PLC tumors.

METHODS

To further enhance the documentation of data pinpointing different phenotypes/subtypes of liver and PLC, we extended the catalog of LiverSCA with additional datasets, e.g., ICC and metabolic dysfunction-associated steatotic liver disease/steatosis (MASLD/MASH).

RESULTS

The current enhanced version of the LiverSCA cell atlas encompasses six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), 63 patients, and over 248,000 cells. Furthermore, we have incorporated comparative visualization methods that allow users to simultaneously examine and compare gene expression levels between two different phenotypes.

CONCLUSIONS

We are committed to the continuous development of LiverSCA and envision that it will serve as a valuable resource to support researchers in convenient investigations into the cellular and molecular landscapes of liver and PLC.

摘要

背景

肝细胞癌(HCC)和肝内胆管癌(ICC)是原发性肝癌(PLC)的两种不同类型,具有相当程度的细胞和分子异质性。我们最近开发了一个名为LiverSCA的基于网络的细胞图谱,它具有用户友好的界面和全面的功能。它有助于探索肝脏和PLC肿瘤微环境中的基因表达模式、细胞组成和细胞间通讯。

方法

为了进一步加强对确定肝脏和PLC不同表型/亚型的数据的记录,我们用额外的数据集(如ICC和代谢功能障碍相关脂肪性肝病/脂肪变性(MASLD/MASH))扩展了LiverSCA的目录。

结果

当前增强版的LiverSCA细胞图谱涵盖六种表型(正常、HBV-HCC、HCV-HCC、非病毒性HCC、ICC和MASH)、63名患者以及超过248,000个细胞。此外,我们纳入了比较可视化方法,允许用户同时检查和比较两种不同表型之间的基因表达水平。

结论

我们致力于LiverSCA的持续开发,并设想它将成为一种有价值的资源,支持研究人员方便地研究肝脏和PLC的细胞和分子景观。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/cd6cd1619522/cancers-17-00890-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/b7c2978a21a6/cancers-17-00890-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/af84a5a79c9c/cancers-17-00890-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/196bbdc36bbd/cancers-17-00890-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/cd6cd1619522/cancers-17-00890-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/b7c2978a21a6/cancers-17-00890-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/af84a5a79c9c/cancers-17-00890-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/196bbdc36bbd/cancers-17-00890-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9be/11898674/cd6cd1619522/cancers-17-00890-g004.jpg

相似文献

1
LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.LiverSCA 2.0:用于人类肝细胞癌和肝内胆管癌的增强型综合细胞图谱。
Cancers (Basel). 2025 Mar 5;17(5):890. doi: 10.3390/cancers17050890.
2
Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.肝细胞癌合并胆管癌和肝内胆管癌的全外显子突变和转录组全景揭示了分子多样性。
Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2360-2368. doi: 10.1016/j.bbadis.2018.01.027. Epub 2018 Feb 1.
3
LiverSCA: A comprehensive and user-friendly cell atlas in human hepatocellular carcinoma.肝脏SCA:一份全面且用户友好的人类肝细胞癌细胞图谱。
Comput Struct Biotechnol J. 2024 Jun 24;23:2740-2745. doi: 10.1016/j.csbj.2024.06.031. eCollection 2024 Dec.
4
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.代谢功能障碍相关脂肪性肝病相关肝肿瘤的病理学与发病机制
Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761.
5
DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.用于原发性肝癌诊断和区分肝细胞癌与肝内胆管细胞癌的 DNA 甲基化生物标志物。
Aging (Albany NY). 2021 Jul 8;13(13):17592-17606. doi: 10.18632/aging.203249.
6
Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.从代谢功能障碍相关脂肪性肝炎向肝细胞癌转变过程中的T细胞介导的适应性免疫
Front Cell Dev Biol. 2024 May 7;12:1343806. doi: 10.3389/fcell.2024.1343806. eCollection 2024.
7
Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.使用日本版基因组图谱对原发性肝癌进行基于分子特征的多组学分析。
J Hepatobiliary Pancreat Sci. 2023 Mar;30(3):269-282. doi: 10.1002/jhbp.1223. Epub 2022 Aug 31.
8
MYC determines lineage commitment in KRAS-driven primary liver cancer development.MYC 决定 KRAS 驱动的原发性肝癌发展中的谱系决定。
J Hepatol. 2023 Jul;79(1):141-149. doi: 10.1016/j.jhep.2023.02.039. Epub 2023 Mar 9.
9
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.富含组氨酸糖蛋白在代谢功能障碍相关脂肪性肝炎相关疾病进展及肝癌发生中的作用
Front Immunol. 2024 Feb 26;15:1342404. doi: 10.3389/fimmu.2024.1342404. eCollection 2024.
10
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.致癌驱动基因和肿瘤微环境决定肝癌的类型。
Cell Death Dis. 2020 May 4;11(5):313. doi: 10.1038/s41419-020-2509-x.

本文引用的文献

1
LiverSCA: A comprehensive and user-friendly cell atlas in human hepatocellular carcinoma.肝脏SCA:一份全面且用户友好的人类肝细胞癌细胞图谱。
Comput Struct Biotechnol J. 2024 Jun 24;23:2740-2745. doi: 10.1016/j.csbj.2024.06.031. eCollection 2024 Dec.
2
Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.恶性细胞与巨噬细胞之间的相互作用增强了乙型肝炎病毒相关性肝细胞癌中的癌症干细胞特性和 M2 极化。
Theranostics. 2024 Jan 1;14(2):892-910. doi: 10.7150/thno.87962. eCollection 2024.
3
GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases.
GepLiver:一个整合的肝脏表达图谱,涵盖了发育阶段和肝脏疾病阶段。
Sci Data. 2023 Jun 10;10(1):376. doi: 10.1038/s41597-023-02257-1.
4
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.非酒精性脂肪性肝炎相关肝细胞癌:发病机制与治疗。
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503. doi: 10.1038/s41575-023-00754-7. Epub 2023 Mar 17.
5
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.多区域单细胞剖析肿瘤和免疫细胞揭示肝癌中稳定的锁钥特征。
Nat Commun. 2022 Dec 7;13(1):7533. doi: 10.1038/s41467-022-35291-5.
6
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.肝内胆管癌治疗进展:临床医生当前及未来治疗前景概述
CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19.
7
Tumor-associated macrophages in liver cancer: From mechanisms to therapy.肝癌相关巨噬细胞:从机制到治疗。
Cancer Commun (Lond). 2022 Nov;42(11):1112-1140. doi: 10.1002/cac2.12345. Epub 2022 Sep 7.
8
A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma.原发性和转移性肝细胞癌的多细胞生态系统单细胞图谱。
Nat Commun. 2022 Aug 6;13(1):4594. doi: 10.1038/s41467-022-32283-3.
9
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.肝细胞癌的分子发病机制和系统治疗。
Nat Cancer. 2022 Apr;3(4):386-401. doi: 10.1038/s43018-022-00357-2. Epub 2022 Apr 28.
10
Immunotherapies for hepatocellular carcinoma.肝细胞癌的免疫疗法
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.